Securities code: 688553 securities abbreviation: Sichuan Huiyu Pharmaceutical Co.Ltd(688553) Announcement No.: 2022-003 Sichuan Huiyu Pharmaceutical Co.Ltd(688553)
Announcement on using part of the over raised funds to invest in the construction of new projects
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important:
Sichuan Huiyu Pharmaceutical Co.Ltd(688553) (hereinafter referred to as “the company” or ” Sichuan Huiyu Pharmaceutical Co.Ltd(688553) “) held the 20th meeting of the first board of directors and the 12th meeting of the first board of supervisors respectively on January 11, 2022, reviewed the proposal on using part of the raised funds to invest in new projects, and agreed that the company would use RMB 315.61 million to invest in new projects, Among them, it is proposed to use 27 million yuan of self owned funds and 288.61 million yuan of over raised funds, accounting for 63.66% of the total over raised funds of the company. The independent directors of the company expressed their independent opinions on the above matters, and the recommendation institution China Securities Co.Ltd(601066) (hereinafter referred to as ” China Securities Co.Ltd(601066) “) issued no objection verification opinions on the above matters. The above matters need to be submitted to the first extraordinary general meeting of shareholders in 2022 for deliberation.
Investment project and amount: the investment amount of the high-end green drug industry chain extension project of the wholly-owned subsidiary Sichuan Zeyu Pharmaceutical Co., Ltd. is 315.61 million yuan, and the proposed over raised fund is 288.61 million yuan.
This investment does not constitute a connected transaction or a major asset restructuring.
Relevant risk tips: during the implementation of the investment project, there may be risks such as failure to implement smoothly and the project does not meet expectations. 1、 Basic information of raised funds
With the approval of the Listing Committee of the science and Innovation Board of Shanghai Stock Exchange on May 26, 2021 and the approval of the China Securities Regulatory Commission on the approval of the registration of Sichuan Huiyu Pharmaceutical Co.Ltd(688553) initial public offering shares (zjxk [2021] No. 2596) on August 3, 2021, Sichuan Huiyu Pharmaceutical Co.Ltd(688553) publicly issued 63600000 RMB common shares (A shares) to the public, The issuance price is 38.87 yuan / share. The total amount of funds raised in this issuance is 2472132000 yuan. After deducting the relevant issuance expenses of 111.4572 million yuan, the net amount of funds raised is 2360674800 yuan. On October 19, 2021, Tianjian Certified Public Accountants (special general partnership) verified the availability of funds for this issuance and issued the capital verification report numbered Tianjian Yan [2021] No. 11-44. According to the requirements of relevant laws and regulations and the measures for the administration of raised funds of listed companies on Shanghai Stock Exchange (revised in 2013), the company has adopted a special account storage system for the raised funds, which has been placed in the special account for raised funds approved by the board of directors after arrival, and the company has cooperated with the sponsor The commercial banks that deposit the raised funds have signed the supervision agreement related to the raised funds. 2、 Deposit and management of raised funds in special accounts
In order to standardize the use and management of raised funds, In accordance with the provisions of laws and regulations such as guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (hereinafter referred to as “regulatory guidelines No. 2”), guidelines for the application of self regulatory rules for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation (hereinafter referred to as “guidelines for the application of regulatory rules No. 1”), etc, The management system of Sichuan Huiyu Pharmaceutical Co.Ltd(688553) raised funds (hereinafter referred to as the “management system of raised funds”) has been formulated, and the raised funds are stored and managed in a special account according to relevant regulations. The company, the sponsor China Securities Co.Ltd(601066) and Bank Of China Limited(601988) Neijiang branch of the bank where the special account of raised funds is located, the business office of Neijiang branch of Leshan Commercial Bank Co., Ltd Neijiang branch, China Merchants Bank Co.Ltd(600036) Chengdu Wuhou sub branch, China Citic Bank Corporation Limited(601998) Chengdu Tianfu sub branch and Shanghai Pudong Development Bank Co.Ltd(600000) Huafu Avenue sub branch of Bank of Sichuan Co., Ltd. signed the tripartite supervision agreement on the storage of special account for raised funds respectively. 3、 Investment projects with raised funds
The net amount of funds actually raised by the company through public offering of shares to the public is 2360674800 yuan, of which the amount of over raised funds is 453359800 yuan. The specific conditions of the company’s investment projects with raised funds are as follows:
Total investment planned to raise fund investment serial number project name
(10000 yuan) (10000 yuan)
Huiyu EU standard injection industrialization
1 base (phase II) project 67941.00 67941.00
Construction project of Huiyu Innovative Drug Research Institute
Mesh 420.792
3. Supplementary working capital project 80000.00 80000.00
Total 190731.50
4、 In order to improve the efficiency of the use of the raised funds, the company plans to use part of the raised funds to invest in the following projects:
The total investment is planned to use the serial number and project name of over raised funds
(10000 yuan) (10000 yuan)
1 high end green drug industry chain extension project 31561 28861
1. Project overview
With Sichuan Zeyu Pharmaceutical Co., Ltd. (hereinafter referred to as “Zeyu pharmaceutical”), a wholly-owned subsidiary of the company, as the main body, the company invests in the construction of high-end green pharmaceutical industry chain extension project, with a construction area of 38264.46m2 and an estimated investment amount of 315.61 million yuan. It plans to use 288.61 million yuan of over raised funds, accounting for 63.66% of the total over raised funds of the company. The project is planned to be built in Neijiang Economic Development Zone, mainly including production workshop, pilot workshop, warehouse, tank farm and other supporting facilities. At the same time, with the help of energy supply, office and quality inspection of Zeyu pharmaceutical, the project mainly produces API such as pemetrexed disodium and atracurium, and carries out pilot scale-up research on API of subsequent preparations of the company. 2. Project filing
Zeyu pharmaceutical filed and applied for the “high-end green drug industry chain extension project of Zeyu pharmaceutical No. 2 branch” on August 4, 2021, and obtained the filing form of fixed asset investment projects in Sichuan Province (Chuantou Zibei [2108-511098-04-01-141231] fgqb-0083) issued by the economic and Technological Development Bureau of Neijiang economic and Technological Development Zone on August 5, 2021. The project has been filed.
3. Project implementation subject
The project is implemented by Zeyu pharmaceutical, a wholly-owned subsidiary of the company. 4. Project implementation location
The project is implemented in the west of Neijiang Suining expressway, the south of hengsi road and the west of Zongyi road. 5. Project construction cycle
The project is planned to be completed in 24 months. 6. Project investment amount and capital source
The total planned investment of the project is 315.61 million yuan, including over raised funds of 288.61 million yuan and self raised funds of 27 million yuan. The investment scale of the project is as follows:
Unit: 10000 yuan
No. proportion of project investment amount
1. Working capital 5396.94 17.10%
2. Equipment purchase cost 8779.00 27.82%
3. Installation cost 4049.14 12.83%
4. Construction cost 8092.61 25.64%
5. Other construction costs 5243.35 16.61%
Total 31561.00 100%
7. Necessity of project implementation (1) improve the quality control of the company’s API: in recent years, China’s medical reform has comprehensively improved the level of drug quality evaluation by issuing a series of policies and systems, adjusting the pharmaceutical industry structure across the board, encouraging and promoting the R & D and production of innovative drugs and high-quality generic drugs, At the same time, the listed varieties of the company are the top three. Through the consistency evaluation, the company has accumulated rich technology and experience in preparation research and production. It is necessary for the company to reasonably optimize resources, coordinate management and control and realize its own control over the quality of API. (2) Create “API preparation” integration and improve the company’s operation efficiency: provide the market with drugs with exquisite quality and reasonable price. It is necessary for the company to realize the production scale effect through the “API preparation” integration construction and reasonably optimize the production capacity layout, build an API production base with cost advantage, and vertically integrate characteristic APIs and the company’s preparations, Realize the independent supply of some APIs, create a more price competitive product pipeline, and improve the comprehensive operation efficiency of the company. (3) The capacity design of the project is planned according to the expected global sales volume of the company’s preparations. Specifically, the construction of the project comprehensively considers the existing production capacity of the company and the expected sales of preparations. At the same time, the project reserves a certain surplus production capacity for external sales. 8. Feasibility of project implementation (1) solid technical foundation
All the technologies involved in the project come from the company’s R & D team. After years of technology accumulation, the company has built a technical platform for API production quality control, including chiral drug R & D, drug crystallization purification and drug preparation purification, mainly involving chiral catalysis, chiral resolution and asymmetric synthesis; Development of compound crystallization process, discovery of dominant crystal forms, industrialization of crystallization process and other technologies; Screening of new fillers, preparation and separation technology, etc. (2) Solid project talent team
Since the establishment of API R & D team in 2018, the company has established an API R & D team with more than 150 people, and has recruited more than 100 engineering and technical personnel related to professional environment and safety, production process and equipment. The project team has rich experience. (3) The project market is expected to be good
The project plans to produce clear varieties and carry out supporting production closely around the company’s main products of EU standard preparations. So far, the company has won the bid for 6 preparations, and the national centralized drug procurement, with more than 80 projects under research, including more than 30 API and excipient projects. After the project is completed and put into operation, it will mainly supply the company’s preparation API demand. At the same time, it will reasonably allocate resources and adjust the supply strategy according to the market situation, so as to supply to the markets outside China. (4) Comply with relevant laws and regulations
The high-end green pharmaceutical industry chain extension project of Zeyu pharmaceutical meets the requirements of national industrial development policies and planning, and the layout and structural adjustment policies of biomedicine (API) industry in Neijiang national economic and Technological Development Zone; The construction of the project has a positive significance in promoting the adjustment and optimization of API industrial structure, technical structure, organizational structure and product structure in Neijiang national economic and Technological Development Zone.
Made in China 2025 takes biomedicine and high-performance medical devices as key development areas. The state continues to take biomedicine and other strategic emerging industries as pillar industries of the national economy, accelerate the cultivation, and continue to implement science and technology plans such as “major new drug creation” science and technology projects, which will contribute to the innovation ability, quality brand Provide strong policy support for the improvement of intelligent manufacturing and green development level.
The notice of the national development and Reform Commission and the Ministry of industry and information technology on the implementation plan for promoting the high-quality development of API industry points out that chemical API is the basic raw material and active ingredient of drugs and an important part of the pharmaceutical industry. The state will continue to provide strong policy support for accelerating the high-quality development of the API industry under the new situation, promoting the improvement of the core competitiveness of the pharmaceutical industry, and orderly promoting the high-quality development of the API industry. 9. Benefit analysis (1) economic benefit analysis of the project
The project is planned to invest 315.61 million yuan. It is planned to complete the decoration work and the installation and commissioning of the first batch of equipment in December 2022. Therefore, 2021 and 2022 are mainly the construction period. At the beginning of 2023, with the availability of personnel and equipment, the project begins to enter the revenue output period. After all normal operations, the estimated annual production capacity is 38053.90kg, The average annual sales revenue of Yuze pharmaceutical is expected to be 6.82 million yuan. (2) Social benefit analysis of the project
Relying on Sichuan Huiyu Pharmaceutical Co.Ltd(688553) ‘s talent and R & D management technology advantages, the project will gradually form a talent cluster effect and enhance regional competitiveness; Technological innovation will further promote the progress of “industry university research” cooperation and strengthen the transformation of achievements.
The project focuses on the fields of high-end antibiotics and antitumor chemicals with high clinical value and great market potential, promotes the industrialization of their API, and builds an efficient, safe and green industrialization demonstration base of new continuous synthesis technology, so as to provide support for the rapid development of the company. It will help the company build an integrated competitive advantage of API preparations.
At the same time, it will play a positive role in promoting the aggregation of regional pharmaceutical industry and the high-quality development of the whole pharmaceutical industry chain in Southwest Sichuan.
